EUVIMEDEUVIMED entdecken
MetaanalyseÜbersichtsarbeit

Meta‐analysis: Placebo rates in microscopic colitis randomised trials and applications for future drug development using a historical control arm

Patrick Hamilton, Katherine Buhler, John K MacDonald, Gilaad G Kaplan iD, Cynthia H Seow iD, Cathy Lu iD, Kerri L Novak iD, Christopher N Andrews iD, Siddharth Singh iD, Vipul Jairath iD, Remo Panaccione iD, Christopher Ma iD

Alimentary Pharmacology & Therapeutics · 2023

DOI: 10.1111/apt.17433 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2023. Verfasst von Patrick Hamilton und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Colitis, Microscopic, Colitis, Collagenous. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Effective medical therapies for patients with microscopic colitis (MC) who fail budesonide are lacking. However, conducting randomised controlled trials (RCTs) in MC has been challenging due to small sample sizes. Understanding placebo responses can help inform more efficient future trials.

Aims

The aim of this study is to estimate clinical and histologic placebo response rates and to determine factors associated with placebo response in MC.

Methods

EMBASE, MEDLINE, and CENTRAL were searched until 7 January 2022, to identify placebo‐controlled RCTs in adult patients with MC. Clinical and histologic response in the placebo arms were pooled using random‐effects models. Stratified analyses based on disease‐ and trial‐level characteristics, leave‐one‐out meta‐analysis, and cumulative meta‐analysis were performed.

Results

Twelve RCTs enrolling a total of 391 patients (placebo n = 163) with MC were included. Pooled clinical and histologic placebo response rates were 24.4% (95% CI: 12.4%–38.4%), I 2 = 60.8%, p < 0.01, and 19.9% (95% CI: 5.3%–39.0%), I 2 = 66.4%, p = 0.01 (tests for heterogeneity), respectively. Clinical response to placebo was numerically higher in patients with lymphocytic compared to collagenous colitis (39.9% vs. 19.8%, p = 0.08). Heterogeneity in clinical response to placebo was significantly reduced when the Miehlke 2014 RCT was excluded in the leave‐one‐out meta‐analysis or when a more stringent secondary definition of response based on the Hjortswang criteria was applied.

Conclusions

Approximately one‐quarter of patients in MC trials respond to placebo, although with substantial heterogeneity, reflecting the need for standardised outcome definitions and study designs for MC. This analysis also serves to inform future MC trials that may consider incorporating an external, historical placebo control arm, rather than directly randomising patients to placebo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, MicroscopicColitis, CollagenousAdultHumansBudesonideRandomized Controlled Trials as Topic

Substanzen

Budesonide

Autor:innen und Institutionen

  • Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Division of Gastroenterology & Hepatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Alimentiv Inc., London, Ontario, Canada.
  • Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Division of Gastroenterology, University of California San Diego, San Diego, California, USA.
  • Division of Gastroenterology, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada.

ORCID-Profile: Gilaad G Kaplan, Cynthia H Seow, Cathy Lu, Kerri L Novak, Christopher N Andrews, Siddharth Singh, Vipul Jairath, Remo Panaccione, Christopher Ma

Zitieren

APA

Hamilton, P., Buhler, K., MacDonald, J. K., Kaplan, G. G., Seow, C. H., Lu, C., Novak, K. L., Andrews, C. N., Singh, S., Jairath, V., Panaccione, R., & Ma, C. (2023). Meta‐analysis: Placebo rates in microscopic colitis randomised trials and applications for future drug development using a historical control arm. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17433

Vancouver

Hamilton P, Buhler K, MacDonald JK, Kaplan GG, Seow CH, Lu C, et al. Meta‐analysis: Placebo rates in microscopic colitis randomised trials and applications for future drug development using a historical control arm. Alimentary Pharmacology & Therapeutics. 2023. doi:10.1111/apt.17433

BibTeX
@article{Hamilton2023,
  author = {Hamilton, Patrick and Buhler, Katherine and MacDonald, John K and Kaplan, Gilaad G and Seow, Cynthia H and Lu, Cathy and Novak, Kerri L and Andrews, Christopher N and Singh, Siddharth and Jairath, Vipul and Panaccione, Remo and Ma, Christopher},
  title = {Meta‐analysis: Placebo rates in microscopic colitis randomised trials and applications for future drug development using a historical control arm},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2023},
  doi = {10.1111/apt.17433}
}
Kostenlos starten →